Indian medical device industry to touch US$ 50 billion by 2030

India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

LVPEI observes World Glaucoma Week

Vision loss due to Glaucoma can be prevented if it is detected and treated early

Ayush gets big boost in the North East

India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid

Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada

Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market

Federal Bank Hormis Memorial Foundation, Tata Trusts and News18 join hands to launch ‘Sanjeevani’

‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic